Q-omics provides the consensus-scored REEP2 profile across patient tissues and cancer cell-line models. REEP2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, REEP2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, REEP2 RNA expression shows 17,208 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where REEP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REEP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REEP2 survival associations across molecular data types. REEP2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REEP2 RNA expression–survival associations across cancer types. High REEP2 expression shows unfavorable associations in UVM, KIRC, ACC, COAD and UCEC, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for REEP2 RNA expression.
This table summarizes REEP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for REEP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REEP2 shows lower tumor expression in KIRC, BLCA and COAD and higher tumor expression in LUAD, THCA and LIHC. The KIRC box plot shows higher REEP2 RNA expression in normal versus tumor tissue (log2 FC = −0.702, t-test p < 0.001).
This table shows molecular features associated with REEP2 in patient tissues and cancer cell lines. In patient samples, REEP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, REEP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
